Education: PhD from the Royal Institute of Technology in Stockholm and an Executive MBA from Stockholm University.
Experience: Christina Herder (born 1961) has 25 years of experience in pharmaceutical development and business development in the life science industry. Her previous assignments include several leading roles in, among others, Swedish Orphan Biovitrum AB (SOBI) and Biovitrum. Christina is currently employed as Executive Vice President, Chief Operating Officer at Medivir AB (listed on Nasdaq, Stockholm) and member of the board of cell therapy company Idogen (First North). Previously, Christina was CEO of Modus Therapeutics, a Swedish drug development company. She has been a board member for PCI Biotech Holding ASA (listed on Oslo Axess) since 2015.
Independency: Christina Herder is independent in relation to the company, its senior executives and major shareholders.
Shares: 50 000 (incl. related parties).